# ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/engot-en11-gog-3053-keynote-b21-a-randomised-double-blind-phase-iii-study-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Toon Van Gorp,David Cibula,Weiguo Lv,Floor Backes,Fırat Ortaç,K. Hasegawa,Kristina Lindemann,Antonella Savarese,Annouschka Laenen,Y.M. Kim,Lisa M. Bodnar,M-P Barretina-Ginesta,L. Gilbert,Bhavana Pothuri,Xiaojun Chen,Marcelo B.S. Flores,Tally Levy,N. Colombo,Christos Papadimitriou,Tommy Buchanan,L.C. Hanker,Gemma Eminowicz,L Rob,D. Black,Jasmine Lichfield,Gen Lin,Robert Orlowski,Stephen J. O’Keefe,Alain Lortholary,Brian M. Slomovitz |
| Citations | 88 |
| DOI | 10.1016/j.annonc.2024.08.2242 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://www.annalsofoncology.org/article/S0923-7534(24)03822-5/pdf |
| OpenAlex ID | https://openalex.org/W4402540651 |
| PMID | 39284383 |
| Type | article |
| Year | 2024 |

## Paper authors

- [Gen Lin](https://scholariq.org/researchers/gen-lin/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)

## Paper topics

- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gynecological conditions and treatments](https://scholariq.org/topics/gynecological-conditions-and-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.